On the stock market since 2020, it operates in the world of health and science. It has 317 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 30% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Growth: Sales growth trails the sector average.
The stock trades 27% below its peak. The market has trimmed its expectations for the company.
Sales run at $84.0M a year. A small number, but proof the product has real buyers.
There is $592.9M in the vault; even if every debt were paid off, $537.2M would remain.
The average analyst price target is $34.67 — 30% above today’s price.
A loss of $264.5M against $84.0M in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
On our five-subject report card, NRIX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NRIX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (35/100) says the stock isn’t cheap.